For instance, amyloid-β and tau proteins are well-established markers, but recent studies have highlighted the importance of other molecules such as neurofilament light (NfL) and phosphorylated tau181 (p-tau181), which have shown promise in distinguishing AD patients from healthy controls (57). Here, MAPT is linked to Alzheimer disease.